MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
March 01 2024 - 9:00AM
Business Wire
- Data update includes 12-week topline Phase 2b
results for MM120 in Generalized Anxiety Disorder (GAD) -
- Results from Phase 1 pharmacokinetics
bridging trial for MM120 oral dissolving tablet (ODT) formulation
to be discussed -
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada:
MMED), (the "Company" or "MindMed"), a clinical stage
biopharmaceutical company developing novel product candidates to
treat brain health disorders, today announced that it will host a
conference call and webcast on March 7, 2024. The program will
provide an update on MM120 in Generalized Anxiety Disorder (GAD),
including 12-week topline safety, efficacy, and durability results
from the Company’s Phase 2b trial and results from the Company’s
Phase 1 pharmacokinetics bridging trial to support the advancement
of the MM120 oral dissolving tablet (ODT) formulation into pivotal
clinical trials.
A live question and answer session will follow the program.
The event will begin at 8:00 a.m. Eastern Time on Thursday,
March 7, 2024. The webcast and slides will be accessible live under
“News & Events” on the Investors page of the Company’s website
at https://ir.mindmed.co/ or by clicking here. A replay of the
event will be available on MindMed’s website.
About MM120
Lysergide is a synthetic ergotamine belonging to the group of
classic psychedelics, which acts as a partial agonist at human
serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors. MindMed
is developing MM120 (lysergide D-tartrate), the tartrate salt form
of lysergide, for GAD and other psychiatric indications.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian Cboe Exchange under the symbol MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240301424341/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Apr 2024 to May 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From May 2023 to May 2024